Cercar
01/10/2022
Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies
Thaci, D, Gerdes, S, Du Jardin, KG, Perrot, JL, Puig, L. Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies. Dermatology and Therapy. 2022; 12(10)DOI:10.1007/s13555-022-00793-z. PMID:36098877. IF:3.400(Q2/3D).
01/09/2022
European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy
Wollenberg, A, Kinberger, M, Arents, B, Aszodi, N, Valle, GA, Barbarot, S, Bieber, T, Brough, HA, Pinton, PC, Christen-Zach, S, Deleuran, M, Dittmann, M, Dressler, C, Fink-Wagner, AH, Fosse, N, Gaspar, K, Gerbens, L, Gieler, U, Girolomoni, G, Gregoriou, S, Mortz, CG, Nast, A, Nygaard, U, Redding, M, Rehbinder, EM, Ring, J, Rossi, M, Serra-Baldrich, E, Simon, D, Szalai, ZZ, Szepietowski, JC, Torrelo, A, Werfel, T, Flohr, C. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(9)DOI:10.1111/jdv.18345. PMID:35980214. IF:9.200(Q1/1D).
01/09/2022
HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience
Piron, M, Salvador, F, Caballero, E, Sanchez-Montalva, A, Bes, M, Casamitjana, N, Puig, L, Molina, I, Sauleda, S. HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience. Viruses-Basel. 2022; 14(9)DOI:10.3390/v14091975. PMID:36146780. IF:4.700(Q2/5D).
18/08/2022
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
Zozaya, N, Abdalla, F, Zamora, SA, Filgueiras, JB, Carrillo, JMC, Sanchez, OD, Sinisterra, FD, Garcia-Ruiz, A, Pinto, PH, Manfredi, A, Olmos, JM, Luna, PMD, Puig, L, Ros, S, HIdalgo-Vega, A. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2022; 22(6)DOI:10.1080/14737167.2022.2063842. PMID:35404728. IF:2.300(Q3/7D).
18/08/2022
Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group
del Alcazar, E, Lopez-Ferrer, A, Martinez-Domenech, A, Julia, M, Ruiz-Villaverde, R, Fernandez-Freire, LR, Notario, J, Llamas-Velasco, M, Ferran, M, Carrascosa, JM. Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(6)DOI:10.1080/09546634.2022.2079596. PMID:35593480. IF:2.900(Q2/4D).
01/08/2022
Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa
Iznardo, H, Vilarrasa, E, Roe, E, Puig, L. Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(8)DOI:10.1111/jdv.18116. PMID:35353931. IF:9.200(Q1/1D).